Final results of a Phase I study of cediranib, a VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors

被引：1
|
作者：
Murakami, H. [1 ]
Yamamoto, N. [1 ,3 ]
Boku, N. [2 ]
Yamazaki, K. [2 ]
Yamamoto, N. [1 ,3 ]
Yamada, Y. [4 ]
Yamada, K. [3 ]
Puchalski, T. [5 ]
Shin, E. [6 ]
Tamura, T. [3 ]
机构：
[1] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka 104, Japan
[2] Shizuoka Canc Ctr, Div Gastrointestinal Oncol & Endoscopy, Shizuoka 104, Japan
[3] Natl Canc Ctr, Div Internal Med, Tokyo, Japan
[4] Natl Canc Ctr, Div Gastrointestinal Oncol, Tokyo, Japan
[5] AstraZeneca, Res & Dev, Wilmington, DE USA
[6] AstraZeneca, Res & Dev, Osaka, Japan
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(08)72328-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：124 / 124
页数：1
相关论文
共 50 条
  • [31] Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors
    Shinji Nakamichi
    Hiroshi Nokihara
    Noboru Yamamoto
    Yasuhide Yamada
    Yutaka Fujiwara
    Yosuke Tamura
    Hiroshi Wakui
    Kazunori Honda
    Hidenori Mizugaki
    Satoru Kitazono
    Yuko Tanabe
    Hajime Asahina
    Naoya Yamazaki
    Shigenobu Suzuki
    Mieko Matsuoka
    Yoshitaka Ogita
    Tomohide Tamura
    Investigational New Drugs, 2015, 33 : 641 - 651
  • [32] PHASE I STUDY OF LY2523355, AN EG5 INHIBITOR, IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
    Nakamichi, S.
    Nokihara, H.
    Mizugaki, H.
    Wakui, H.
    Fujiwara, Y.
    Yamada, Y.
    Yamamoto, N.
    Suzuki, K.
    Akinaga, S.
    Tamura, T.
    ANNALS OF ONCOLOGY, 2013, 24
  • [33] Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors
    Nakamichi, Shinji
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Yamada, Yasuhide
    Fujiwara, Yutaka
    Tamura, Yosuke
    Wakui, Hiroshi
    Honda, Kazunori
    Mizugaki, Hidenori
    Kitazono, Satoru
    Tanabe, Yuko
    Asahina, Hajime
    Yamazaki, Naoya
    Suzuki, Shigenobu
    Matsuoka, Mieko
    Ogita, Yoshitaka
    Tamura, Tomohide
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (03) : 641 - 651
  • [34] A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors
    Jonker, D. J.
    Rosen, L. S.
    Sawyer, M. B.
    de Braud, F.
    Wilding, G.
    Sweeney, C. J.
    Jayson, G. C.
    McArthur, G. A.
    Rustin, G.
    Goss, G.
    Kantor, J.
    Velasquez, L.
    Syed, S.
    Mokliatchouk, O.
    Feltquate, D. M.
    Kollia, G.
    Nuyten, D. S. A.
    Galbraith, S.
    ANNALS OF ONCOLOGY, 2011, 22 (06) : 1413 - 1419
  • [35] Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors
    Mross, Klaus
    Stefanic, Martin
    Gmehling, Daniela
    Frost, Annette
    Baas, Franziska
    Unger, Clemens
    Strecker, Ralph
    Henning, Juergen
    Gaschler-Markefski, Birgit
    Stopfer, Peter
    de Rossi, Lothar
    Kaiser, Rolf
    CLINICAL CANCER RESEARCH, 2010, 16 (01) : 311 - 319
  • [36] A phase I, open-label, multicenter study of cediranib and AZD0530 in patients with advanced solid tumors
    Trarbach, T.
    Drevs, J.
    Strumberg, D.
    Gauler, T. C.
    Schneider, V.
    Eberhardt, W. E.
    Marotti, M.
    Puchalski, T. A.
    Swaisland, A. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [37] Phase I study of the irreversible FGFR inhibitor futibatinib in Japanese patients with advanced solid tumors: Updated dose expansion results and activity in gastric cancer
    Kuboki, Y.
    Shitara, K.
    Morizane, C.
    Kojima, T.
    Yoh, K.
    Sakai, D.
    Tahara, M.
    Hirai, H.
    Kurokawa, Y.
    Kato, T.
    Doi, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S1047 - S1048
  • [38] Phase I study of BAY 73-4506, an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors: Final results of a dose-escalation study
    Frost, A.
    Buechert, M.
    Unger, C.
    Christensen, O.
    Wagner, A.
    Heinig, R. A.
    Scheulen, M. E.
    Strumberg, D.
    Fasol, U.
    Mross, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [39] Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors
    Fujiwara, Yutaka
    Nokihara, Hiroshi
    Yamada, Yasuhide
    Yamamoto, Noboru
    Sunami, Kuniko
    Utsumi, Hirofumi
    Asou, Hiroya
    Takahash, Osamu, I
    Ogasawara, Ken
    Gueorguieva, Ivelina
    Tamura, Tomohide
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (06) : 1143 - 1152
  • [40] A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors
    Toshihiko Doi
    Nozomu Fuse
    Takayuki Yoshino
    Takashi Kojima
    Hideaki Bando
    Hideaki Miyamoto
    Masato Kaneko
    Motonobu Osada
    Atsushi Ohtsu
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 89 - 98
12345